These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37584249)

  • 1. Sotatercept as a next-generation therapy for pulmonary arterial hypertension: insights from the STELLAR trial.
    Kopeć G
    Cardiovasc Res; 2023 Dec; 119(16):e155-e157. PubMed ID: 37584249
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
    Hoeper MM; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Souza R; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Xu Y; Miller B; Fowler M; Butler J; Koglin J; de Oliveira Pena J; Humbert M;
    N Engl J Med; 2023 Apr; 388(16):1478-1490. PubMed ID: 36877098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman A; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; Barnes J; Linde PG; de Oliveira Pena J; Badesch DB;
    N Engl J Med; 2021 Apr; 384(13):1204-1215. PubMed ID: 33789009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unsolved Issues on Beneficial Effects of Combination Therapy With Sotatercept in Pulmonary Arterial Hypertension.
    Benincasa G; Strozziero MG; Trama U; Napoli C
    Heart Lung Circ; 2024 Jan; 33(1):12-13. PubMed ID: 38040502
    [No Abstract]   [Full Text] [Related]  

  • 5. Sotatercept for pulmonary arterial hypertension: something old and something new.
    Rubin LJ; Naeije R
    Eur Respir J; 2023 Jan; 61(1):. PubMed ID: 36609525
    [No Abstract]   [Full Text] [Related]  

  • 6. Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH).
    McLaughlin V; Alsumali A; Liu R; Klok R; Martinez EC; Nourhussein I; Bernotas D; Chevure J; Pausch C; De Oliveira Pena J; Lautsch D; Hoeper MM
    Adv Ther; 2024 Jan; 41(1):130-151. PubMed ID: 37851297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting.
    Torbic H; Tonelli AR
    J Cardiovasc Pharmacol Ther; 2024; 29():10742484231225310. PubMed ID: 38361351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?
    Doggrell SA
    Expert Opin Biol Ther; 2023; 23(7):589-593. PubMed ID: 37269300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension.
    Liao K; Mackenzie H; Ait-Oudhia S; Manimaran S; Zeng Y; Akers T; Yun T; de Oliveira Pena J
    Clin Pharmacol Ther; 2024 Mar; 115(3):478-487. PubMed ID: 38012534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sotatercept on lung diffusion capacity and blood gases in patients with pulmonary arterial hypertension.
    Olsson KM; Fuge J; Park DH; Kamp JC; Brod T; Harrigfeld B; Schupp JC; Hoeper MM
    Eur Respir J; 2023 Aug; 62(2):. PubMed ID: 37474157
    [No Abstract]   [Full Text] [Related]  

  • 11. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension.
    Joshi SR; Liu J; Bloom T; Karaca Atabay E; Kuo TH; Lee M; Belcheva E; Spaits M; Grenha R; Maguire MC; Frost JL; Wang K; Briscoe SD; Alexander MJ; Herrin BR; Castonguay R; Pearsall RS; Andre P; Yu PB; Kumar R; Li G
    Sci Rep; 2022 May; 12(1):7803. PubMed ID: 35551212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor-β(1) represses bone morphogenetic protein-mediated Smad signaling in pulmonary artery smooth muscle cells via Smad3.
    Upton PD; Davies RJ; Tajsic T; Morrell NW
    Am J Respir Cell Mol Biol; 2013 Dec; 49(6):1135-45. PubMed ID: 23937428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle.
    Price LC; McCabe C; Weatherald J
    Eur Respir J; 2023 Sep; 62(3):. PubMed ID: 37696566
    [No Abstract]   [Full Text] [Related]  

  • 14. Merck bets on sotatercept in pulmonary arterial hypertension.
    Carvalho T
    Nat Med; 2023 Jan; 29(1):2-3. PubMed ID: 36396929
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial.
    Souza R; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Lin J; Johnson-Levonas AO; de Oliveira Pena J; Humbert M; Hoeper MM
    Eur Respir J; 2023 Sep; 62(3):. PubMed ID: 37696565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of overactive transforming growth factor-β signaling by prostacyclin analogs in pulmonary arterial hypertension.
    Ogo T; Chowdhury HM; Yang J; Long L; Li X; Torres Cleuren YN; Morrell NW; Schermuly RT; Trembath RC; Nasim MT
    Am J Respir Cell Mol Biol; 2013 Jun; 48(6):733-41. PubMed ID: 23418342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins.
    Morrell NW; Yang X; Upton PD; Jourdan KB; Morgan N; Sheares KK; Trembath RC
    Circulation; 2001 Aug; 104(7):790-5. PubMed ID: 11502704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raising the bar: triple therapy for pulmonary arterial hypertension associated with congenital heart disease.
    D'Alto M; Bassareo PP
    Heart; 2024 Feb; 110(5):309-310. PubMed ID: 37903554
    [No Abstract]   [Full Text] [Related]  

  • 19. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman AB; Ghofrani HA; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; de Oliveira Pena J; Badesch DB
    Eur Respir J; 2023 Jan; 61(1):. PubMed ID: 36041750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline.
    Thomas M; Docx C; Holmes AM; Beach S; Duggan N; England K; Leblanc C; Lebret C; Schindler F; Raza F; Walker C; Crosby A; Davies RJ; Morrell NW; Budd DC
    Am J Pathol; 2009 Feb; 174(2):380-9. PubMed ID: 19116361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.